Second-quarter 2018 sales stable(3) with strong contributions from Specialty Care and Emerging Markets
Net sales were €8,176 million, down 5.7% on a reported basis, up 0.1%(3) at CER and down 2.5% at CER/CS (4).
Sanofi Genzyme sales up 14.1% at CER/CS (4) (33.1% at CER) driven by Dupixent® and consolidation of Bioverativ.
Vaccines sales down 15.7% reflecting high basis for comparison and expected Pentaxim® supply constraint in China.
CHC sales increased 4.1% supported by growth in Europe and Emerging Markets(5).
DCV(6) GBU sales down 15.6%; global Diabetes franchise sales declined 11.9%, confirming expected trend for year.
Emerging Markets sales(5) increased 5.2% with double-digit growth in China.
2018 business EPS guidance range slightly narrowed
Second-quarter 2018 business EPS(1) up 1.5% at CER to €1.25.
Second-quarter 2018 IFRS EPS was €0.61 (-25.6%).
Business EPS(1) in 2018 now expected to grow 3% to 5% at CER(7) barring unforeseen major adverse events.
Currency impact on 2018 business EPS is estimated to be around -6% applying the average July exchange rates.
Key achievements in sustaining innovation in R&D
Sanofi completed the acquisition of Ablynx in May, internalizing the innovative Nanobody® platform.
Positive CHMP recommendation for CabliviTM for aTTP(8).
Phase 1/2a data on BIVV001, an extended factor VIII therapy, demonstrated half-life of 37 hours.
A phase 2/3 study is being initiated on venglustat, an oral glucosylceramide synthase (GCS) inhibitor, in ADPKD(9).
Positive phase 3 trial evaluating Dupixent® to treat moderate-to-severe atopic dermatitis in adolescents.
Priority review granted in the U.S. to cemiplimab for the treatment of CSCC(10).
ZynquistaTM (sotagliflozin) accepted for review by the FDA in type 1 diabetes.
Praluent® ODYSSEY OUTCOMES results submitted to the FDA and EMA in Q2.
|
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.